
<![CDATA[FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease]]>
The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or Crohn disease who have received at least 1 approved …